Malignant Pleural Mesothelioma clinical trials

Explore recruiting malignant pleural mesothelioma clinical trials.

Recruiting malignant pleural mesothelioma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Malignant Pleural Mesothelioma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

FAPI PET in Pleural Mesothelioma: The Diagnostic Accuracy and Clinical Value of FAPI PET at Diagnosis, Primary Staging, and the Feasibility of FAPI PET for Response Evaluation

Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

PEMbrolizumab Plus Lenvatinib In Second Line And Third Line Malignant Pleural MEsotheLiomA Patients: A Single Arm Phase II Study (PEMMELA).

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

PHASE III STUDY WITH ATEZOLIZUMAB VERSUS PLACEBO IN MALIGNANT PLEURAL MESOTHELIOMA PATIENTS AFTER PLEURECTOMY/DECORTICATION

Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

Phase II study of pembrolizumab in combination with cisplatin or carboplatin and pemetrexed as induction chemo+immunotherapy in resectable epithelioid and biphasic pleural mesothelioma (CHIMERA study)

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

IMPALA Protocol: Intrapleural Photodynamic Therapy by Video-Assisted Thoracoscopy Followed by Anti-PD-1 NIVOLUMAB in Patients With Malignant Pleural Mesothelioma - a Pilot Study -

France

Therapeutic exploratory (Phase II) EU CTIS Study details

First-line immunotherapy using Wilms’ tumor protein 1 (WT1)-targeted dendritic cell vaccinations for malignant pleural mesothelioma

Belgium

Therapeutic exploratory (Phase II) EU CTIS Study details

Malignant Pleural Mesothelioma trials by city

Malignant Pleural Mesothelioma in Toronto Malignant Pleural Mesothelioma in Vancouver Malignant Pleural Mesothelioma in Montreal Malignant Pleural Mesothelioma in Calgary Malignant Pleural Mesothelioma in Edmonton Malignant Pleural Mesothelioma in Ottawa Malignant Pleural Mesothelioma in Winnipeg Malignant Pleural Mesothelioma in Quebec City Malignant Pleural Mesothelioma in Hamilton Malignant Pleural Mesothelioma in Kitchener Malignant Pleural Mesothelioma in London Malignant Pleural Mesothelioma in Halifax Malignant Pleural Mesothelioma in New York Malignant Pleural Mesothelioma in Los Angeles Malignant Pleural Mesothelioma in Chicago Malignant Pleural Mesothelioma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease